株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

OpportunityAnalyzer:敗血症・敗血症性ショック - 市場機会の分析と将来予測

OpportunityAnalyzer: Sepsis and Septic Shock - Opportunity Analysis and Forecasts to 2026

発行 GlobalData 商品コード 574488
出版日 ページ情報 英文 318 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.93円で換算しております。
Back to Top
OpportunityAnalyzer:敗血症・敗血症性ショック - 市場機会の分析と将来予測 OpportunityAnalyzer: Sepsis and Septic Shock - Opportunity Analysis and Forecasts to 2026
出版日: 2017年08月01日 ページ情報: 英文 318 Pages
概要

世界の敗血症・敗血症性ショック治療薬の市場規模は、2015年には28億米ドルと推計されています。また、2016~2026年のCAGR (複合年間成長率) は7.9%、2026年の市場規模は59億米ドルに達する見通しです。

当レポートでは、敗血症および敗血症性ショックの治療薬に関する最新の研究・開発動向と、今後の市場動向の見通しとを分析し、疾患の概要や現段階の治療法、アンメットニーズ・市場機会の評価、今後10年間の発症件数・市場規模の予測値、臨床試験の進行状況、新規治療薬のパイプライン評価、今後の市場・技術動向などを調査・予測しております。

第1章 目次

第2章 敗血症・敗血症性ショック:エグゼクティブ・サマリー

第3章 イントロダクション

  • 背景事情
  • 関連分析
  • 刊行予定の関連分析

第4章 疾患概要

  • 病態と病因
  • 病期分類システム
  • 症状
  • 予後
  • 生活の質 (QoL)

第5章 疫学

  • 疾患の背景事情
  • リスク要因と共存症
  • 世界的な傾向
  • 予測手法
    • 情報源
    • 予測の前提条件・手法
    • 敗血症の受診済み発症者数
    • 敗血症性ショックの受診済み発症者数
    • 敗血症/敗血症性ショックの受診済み発症者数、病原体別
    • 敗血症の受診済み発症者数のうち、臓器障害に陥った人数
    • 敗血症性ショックの受診済み発症者数のうち、臓器障害に陥った人数
    • 敗血症の院内死亡率
    • 敗血症性ショックの院内死亡率
  • 敗血症/敗血症性ショックの疫学的予測 (通算11年間分)
    • 敗血症:受診済み発症者数
    • 敗血症:年齢層別の受診済み発症者数
    • 敗血症:男女別の受診済み発症者数
    • 敗血症:病原体別の受診済み発症者数
    • 敗血症:受診済み発症者数のうち、臓器障害に陥った人数
    • 敗血症:院内死亡率
    • 敗血症:年齢層別の院内死亡率
    • 敗血症性ショック:受診済み発症者数
    • 敗血症性ショック:年齢層別の受診済み発症者数
    • 敗血症性ショック:男女別の受診済み発症者数
    • 敗血症性ショック:病原体別の受診済み発症者数
    • 敗血症性ショック:受診済み発症者数のうち、臓器障害に陥った人数
    • 敗血症性ショック:院内死亡率
    • 敗血症性ショック:年齢層別の院内死亡率
  • 議論
    • 疫学的な予測結果に関する考察
    • 分析の限界
    • 分析の強み

第6章 現在の治療オプション

  • 概要
  • 診断・治療
    • 診断
    • 治療ガイドライン
  • 臨床診療
    • 概要
    • 一連の敗血症啓発キャンペーン
    • 国ごとの差異
  • 感染予防:抗生物質と他の抗感染症薬
    • 概要
    • 抗生物質療法のタイミング
    • 抗生物質の投与量
    • 抗生物質への耐性
    • その他の治療薬:抗ウイルス剤、抗真菌剤、駆虫薬
  • 敗血症・敗血症性ショックの支持治療オプション
    • 概要
    • 急速輸液、昇圧薬、ドブタミン、輸血
    • 機械的人工呼吸、血液透析
  • 敗血症・敗血症性ショックの他の治療アプローチ

第7章 アンメットニーズの評価と機会分析

  • 概要
  • バイオマーカーの改良による、治療の意思決定の誘導と薬剤開発の支援
    • アンメットニーズ
    • ギャップ分析
    • 市場機会
  • 敗血症の病態生理を対象とした、新たな治療介入
  • 臨床成果改善のための、現在利用可能な介入法の効率化
  • 治験・創薬の促進に向けた、規制枠組みの合理化
  • 信頼性のより高いアニマルモデルを用いた、有力候補の効率的なスクリーニング手法の推進
  • 医療従事者・社会全体の認識改善

第8章 研究開発 (R&D) 戦略

  • 概要
    • 新たなSEPSIS-3合意の定義による、今後の研究開発 (R&D) 努力の誘導
    • 最終段階での介入用の免疫刺激剤
    • その他の特別な開発戦略
    • 早期介入のための抗炎症剤 (IFX-1、トレミキシン)
  • 治験のデザイン
    • 概要
    • 従来型の治験デザイン
    • 応用可能な治験デザイン
    • 治験参加者の参加基準
    • エンドポイント

第9章 パイプライン分析

  • 概要
  • 治験段階にある将来有望な医薬品
    • Selepressin
    • トロンボモジュリン (ART-123)
    • recAP
    • Traumakine (遺伝子組み換えヒトIFN-B-1a)
    • BMS-936559
    • CYT107
    • Cefiderocol
    • Toraymyxin (PMX-20R)
    • CytoSorb
  • 治験の初期段階にある、その他の革新的なアプローチ
    • IFX-1
    • LB1148 (トラネキサム酸)
    • ALT-836
    • Salvecin
    • Opdivo (ニボルマブ)
    • Adrecizumab
    • LGT-209
  • 開発中のその他の医薬品k
    • Cx-611
    • HU-003
    • 備蓄ヒト血漿
    • BMS-986189
    • Motrem

第10章 パイプライン評価の分析

  • 主なパイプライン薬剤の臨床面での基準
  • 主なパイプライン薬剤の商業面での基準
  • 競争力の評価
  • 主要国市場の将来予測 (今後10年間分)
    • 米国
    • 欧州主要5ヶ国 (5EU)
    • 日本

第11章 付録

図表一覧

目次
Product Code: GDHC071POA

Sepsis is a complex disease, which not only involves a wide array of causative agents, but also results in different individual immune responses causing various single or multiple organ dysfunction(s). In late 2016, the sepsis and septic shock market abandoned the concept of a systemic immune response syndrome in the presence of an infection as a potential cause for sepsis; in the new consensus definitions, sepsis is defined as an infection leading to organ dysfunction.

It is estimated that in 2015, the overall sales for sepsis and septic shock to be approximately US$2.8 Billion, comprising annual drug sales of US$2.2 Billion in sepsis and US$0.6 Billion in septic shock across the 7MM. Differences in revenue generated by disease area are due to higher incidence rates for sepsis compared with septic shock. GlobalData expects the sepsis and septic shock market to grow by a strong Compound Annual Growth Rate (CAGR) of 7.9% from 2016-2026, reaching annual sales of US$5.9 Billion by the end of the forecast period.

In order to combat these market realities, we believe developers will have to leverage innovative R&D strategies to establish the strong clinical evidence needed for approval and uptake post-licensure. Some of the key approaches identified by KOLs include adaptive clinical trial design, including interim analyses leveraging multiple clinically relevant biomarkers and companion diagnostics to limit heterogeneity among enrolled patients; targeting highly specific sepsis patient populations based on sepsis-induced conditions; and investigating novel targets with combination therapies that are relevant to sepsis pathophysiology.

The report "OpportunityAnalyzer: Sepsis and Septic Shock - Opportunity Analysis and Forecasts to 2026", covers overview of sepsis and septic shock, including epidemiology, etiology, pathophysiology, as well as current routine sepsis and septic shock recommendations of all 7MM covered.

This report provides the following in-depth analysis -

  • Top-line sepsis and septic shock market revenue from 2016-2026. Recent acquisitions, approvals and governmental recommendations are included in the forecast model.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, R&D strategies, clinical trial design, and influence of new consensus definitions for the sepsis and septic shock market.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and analysis of late-stage pipeline products. An interactive clinical and commercial analyzer tool is available.
  • Analysis of the current and future market competition in the global sepsis and septic shock marketplace. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Companies mentioned in this report: AM-Pharma, Asahi Kasei Pharma Corp, Bristol-Myers Squibb, CytoSorbents, Faron, Ferring Holding, Pfizer, RevImmune, Shionogi, Spectral Diagnostics.

Scope

  • Overview of sepsis and septic shock, including epidemiology, etiology, pathophysiology, as well current routine sepsis and septic shock recommendations of all 7MM covered.
  • Top-line sepsis and septic shock market revenue from 2016-2026. Recent acquisitions, approvals and governmental recommendations are included in the forecast model.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, R&D strategies, clinical trial design, and influence of new consensus definitions for the sepsis and septic shock market.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and analysis of late-stage pipeline products. An interactive clinical and commercial analyzer tool is available.
  • Analysis of the current and future market competition in the global sepsis and septic shock marketplace. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global sepsis and septic shock market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the sepsis and septic shock market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 7
  • 1.2 List of Figures 8

2 Sepsis and Septic Shock: Executive Summary 10

  • 2.1 Global Sepsis and Septic Shock Market to Experience Strong Growth on Launch of First-in-Class Pipeline Products 11
  • 2.2 Developers Must Leverage Innovative R&D Strategies to Target Appropriate Patients and Achieve Sustained Commercial Success 13
  • 2.3 A High Level of Unmet Need Persists in the Sepsis and Septic Shock Marketplace 13
  • 2.4 Opportunities Remain for Current and Future Players to Develop Therapies Targeting Sepsis-Specific Pathophysiology 14
  • 2.5 Immunomodulating Therapies Poised to Transform Sepsis and Septic Shock Market, but Missing Biomarkers Will Limit Their Utility 15
  • 2.6 What Do Physicians Think? 17

3 Introduction 20

  • 3.1 Catalyst 20
  • 3.2 Related Reports 21
  • 3.3 Upcoming Related Reports 21

4 Disease Overview 22

  • 4.1 Etiology and Pathophysiology 22
    • 4.1.1 Etiology 22
    • 4.1.2 Pathophysiology 34
  • 4.2 Classification or Staging Systems 44
  • 4.3 Symptoms 46
  • 4.4 Prognosis 46
  • 4.5 Quality of Life 47

5 Epidemiology 48

  • 5.1 Disease Background 48
  • 5.2 Risk Factors and Comorbidities 49
  • 5.3 Global and Historical Trends 50
  • 5.4 Forecast Methodology 52
    • 5.4.1 Sources 52
    • 5.4.2 Forecast Assumptions and Methods 60
    • 5.4.3 Diagnosed Incident Cases of Sepsis 60
    • 5.4.4 Diagnosed Incident Cases of Septic Shock 64
    • 5.4.5 Diagnosed Incident Cases of Sepsis/Septic Shock by Causative Agent 66
    • 5.4.6 Organ Dysfunction among Diagnosed Incident Cases of Sepsis 69
    • 5.4.7 Organ Dysfunction among Diagnosed Incident Cases of Septic Shock 72
    • 5.4.8 Sepsis In-Hospital Mortality Cases 74
    • 5.4.9 Septic Shock In-Hospital Mortality Cases 77
  • 5.5 Epidemiological Forecast for Sepsis and Septic Shock (2016-2026) 80
    • 5.5.1 Diagnosed Incident Cases of Sepsis 80
    • 5.5.2 Age-Specific Diagnosed Incident Cases of Sepsis 81
    • 5.5.3 Sex-Specific Diagnosed Incident Cases of Sepsis 82
    • 5.5.4 Diagnosed Incident Cases of Sepsis by Causative Agent 83
    • 5.5.5 Organ Dysfunction among Diagnosed Incident Cases of Sepsis 84
    • 5.5.6 Sepsis In-Hospital Mortality Cases 84
    • 5.5.7 Age-Specific In-Hospital Mortality Cases of Sepsis 85
    • 5.5.8 Diagnosed Incident Cases of Septic Shock 86
    • 5.5.9 Age-Specific Diagnosed Incident Cases of Septic Shock 87
    • 5.5.10 Sex-Specific Diagnosed Incident Cases of Septic Shock 88
    • 5.5.11 Diagnosed Incident Cases of Septic Shock by Causative Agent 89
    • 5.5.12 Organ Dysfunction among Diagnosed Incident Cases of Septic Shock 90
    • 5.5.13 Septic Shock In-Hospital Mortality Cases 91
    • 5.5.14 Age-Specific In-Hospital Mortality Cases of Septic Shock 92
  • 5.6 Discussion 93
    • 5.6.1 Epidemiological Forecast Insight 93
    • 5.6.2 Limitations of Analysis 95
    • 5.6.3 Strengths of Analysis 95

6 Current Treatment Options 97

  • 6.1 Overview 97
  • 6.2 Diagnosis and Treatment 99
    • 6.2.1 Diagnosis 99
    • 6.2.2 Treatment Guidelines 105
  • 6.3 Clinical Practice 107
    • 6.3.1 Overview 107
    • 6.3.2 Surviving Sepsis Campaign Bundles 108
    • 6.3.3 Country Differences 109
  • 6.4 Infection Control - Antibiotics and other Anti-infectives 111
    • 6.4.1 Overview 111
    • 6.4.2 Timing of Antibiotic Therapy 113
    • 6.4.3 Dosing of Antibiotic Therapy 115
    • 6.4.4 Antibiotic Resistance 116
    • 6.4.5 Other Therapies - Antivirals, Antifungals, and Antiparasitics 117
  • 6.5 Supportive Treatment Options for Sepsis and Septic Shock 118
    • 6.5.1 Overview 118
    • 6.5.2 Fluid Resuscitation, Vasopressors, Dobutamine, and Blood Transfusion 119
    • 6.5.3 Mechanical Ventilation and Hemodialysis 121
  • 6.6 Other Therapeutic Approaches to Sepsis and Septic Shock 122

7 Unmet Needs Assessment and Opportunity Analysis 124

  • 7.1 Overview 124
  • 7.2 Improved Biomarkers to Guide Treatment Decisions and Support Drug Development 125
    • 7.2.1 Unmet Need 125
    • 7.2.2 Gap Analysis 128
    • 7.2.3 Opportunity 129
  • 7.3 Novel Therapeutic Interventions Targeting Sepsis Pathophysiology 130
    • 7.3.1 Unmet Need 130
    • 7.3.2 Gap Analysis 131
    • 7.3.3 Opportunity 133
  • 7.4 Enhancing Effectiveness of Currently Available Interventions to Help Improve Clinical Outcomes 134
    • 7.4.1 Unmet Need 134
    • 7.4.2 Gap Analysis 136
    • 7.4.3 Opportunity 137
  • 7.5 Streamlined Regulatory Framework to Stimulate Clinical Research and Drug Development 138
    • 7.5.1 Unmet Need 138
    • 7.5.2 Gap Analysis 139
    • 7.5.3 Opportunity 140
  • 7.6 More reliable animal models to facilitate effective screening of lead candidates 141
    • 7.6.1 Unmet Need 141
    • 7.6.2 Gap Analysis 143
    • 7.6.3 Opportunity 144
  • 7.7 Improved Awareness among Healthcare Workers and the Public 144
    • 7.7.1 Unmet Need 144
    • 7.7.2 Gap Analysis 145
    • 7.7.3 Opportunity 146

8 Research and Development Strategies 147

  • 8.1 Overview 147
    • 8.1.1 New SEPSIS-3 Consensus Definition to Guide Future R&D Efforts 150
    • 8.1.2 Immuno-stimulatory Drugs for Late-Step Intervention 151
    • 8.1.3 Other Specific Development Strategies 156
    • 8.1.4 Anti-inflammatory Drugs for Early Intervention (IFX-1, Toraymyxin) 158
  • 8.2 Clinical Trial Design 161
    • 8.2.1 Overview 161
    • 8.2.2 Traditional Clinical Trial Design 162
    • 8.2.3 Adaptive Clinical Trial Design 163
    • 8.2.4 Participant Enrolment Criteria 166
    • 8.2.5 Endpoints 170

9 Pipeline Assessment 172

  • 9.1 Overview 172
  • 9.2 Promising Drugs in Clinical Development 173
    • 9.2.1 Selepressin 176
    • 9.2.2 Thrombomodulin (ART-123) 181
    • 9.2.3 recAP 190
    • 9.2.4 Traumakine (Recombinant Human IFN-B-1a) 195
    • 9.2.5 BMS-936559 198
    • 9.2.6 CYT107 203
    • 9.2.7 Cefiderocol 208
    • 9.2.8 Toraymyxin (PMX-20R) 210
    • 9.2.9 CytoSorb 218
  • 9.3 Other Innovative Early-Stage Approaches 221
    • 9.3.1 IFX-1 221
    • 9.3.2 LB1148 (tranexamic acid) 222
    • 9.3.3 ALT-836 223
    • 9.3.4 Salvecin 226
    • 9.3.5 Opdivo (nivolumab) 226
    • 9.3.6 Adrecizumab 227
    • 9.3.7 LGT-209 228
  • 9.4 Other Drugs in Development 229
    • 9.4.1 Cx-611 229
    • 9.4.2 HU-003 230
    • 9.4.3 Pooled Human Plasma 230
    • 9.4.4 BMS-986189 230
    • 9.4.5 Motrem 231

10 Pipeline Valuation Analysis 232

  • 10.1 Clinical Benchmark of Key Pipeline Drugs 232
  • 10.2 Commercial Benchmark of Key Pipeline Drugs 235
  • 10.3 Competitive Assessment 238
  • 10.4 Top-Line 10-Year Forecast 242
    • 10.4.1 US 248
    • 10.4.2 5EU 253
    • 10.4.3 Japan 258

11 Appendix 263

  • 11.1 Bibliography 263
  • 11.2 Abbreviations 291
  • 11.3 Methodology 297
  • 11.4 Forecasting Methodology 297
    • 11.4.1 Diagnosed Sepsis and Septic Shock Patients 297
    • 11.4.2 Percent Drug-Treated Patients 298
    • 11.4.3 Drugs Included in Each Therapeutic Class 298
    • 11.4.4 Launch and Patent Expiry Dates 299
    • 11.4.5 General Pricing Assumptions 300
    • 11.4.6 Individual Drug Assumptions 301
    • 11.4.7 Generic Erosion 308
    • 11.4.8 Pricing of Pipeline Agents 308
  • 11.5 Primary Research - KOLsInterviewed for this Report 311
  • 11.6 Primary Research - Prescriber Survey 313
  • 11.7 About the Authors 314
    • 11.7.1 Analyst 314
    • 11.7.2 Therapy Area Director 314
    • 11.7.3 Epidemiologist 315
    • 11.7.4 Managing Epidemiologists 315
    • 11.7.5 Global Director of Therapy Analysis and Epidemiology 316
    • 11.7.6 Global Head and EVP of Healthcare Operations and Strategy 317
  • 11.8 About GlobalData 317
  • 11.9 Contact Us 317
  • 11.10 Disclaimer 318

List of Tables

  • Table 1: Sepsis and Septic Shock: Key Metrics in the Seven Major Pharmaceutical Markets 10
  • Table 2: Guidelines for Stratification of Patients with SIRS, Sepsis, Severe Sepsis, and Septic Shock 23
  • Table 3: SEPSIS-2 Diagnostic Criteria (SIRS, Sepsis, Severe Sepsis, and Septic Shock) 29
  • Table 4: SEPSIS-3 Diagnostic Criteria (qSOFA, SOFA, Sepsis, and Septic Shock) 30
  • Table 5: Summary of Pathophysiological Events Causing Sepsis and Septic Shock 37
  • Table 6: Mediators of the Pro-inflammatory and Anti-inflammatory Responses 44
  • Table 7: ICD-10-CM Diagnosis Codes for Sepsis 45
  • Table 8: Symptoms Associated with Sepsis and Septic Shock 46
  • Table 9: Risk Factors and Comorbidities for Sepsis and Septic Shock 50
  • Table 10: 7MM, Diagnosed Incident Cases of Sepsis, Both Sexes, All Ages, Selected Years 2016-2026 80
  • Table 11: 7MM, Sepsis In-Hospital Mortality Cases, Both Sexes, All Ages, Selected Years 2016-2026 85
  • Table 12: 7MM, Diagnosed Incident Cases of Septic Shock, Both Sexes, All Ages, Selected Years 2016-2026 87
  • Table 13: 7MM, Septic Shock In-Hospital Mortality Cases, Both Sexes, All Ages, Selected Years 2016-2026 92
  • Table 14: Key Differences in Diagnosis Criteria according to new SEPSIS-3 102
  • Table 15: Treatment Guidelines for Sepsis and Septic Shock, 2017 105
  • Table 16:SSC Guidelines Compared 106
  • Table 17: Treatment Bundles for Sepsis Patients 109
  • Table 18: Commonly Used Antibiotics in Sepsis and Septic Shock and Important Gaps in Coverage, 2017 112
  • Table 19: Pivotal Studies of Timing of Antibiotic Treatment in Sepsis and Septic Shock 114
  • Table 20: Other Supportive Therapies To Be Implemented When Clinically Relevant 119
  • Table 21: Evolution of the Standard of Care in Sepsis and Septic Shock, 2017 120
  • Table 22: Summary of Minor Supportive Measures, 2017 123
  • Table 23: Key Strategies Pursued by Current Sepsis and Septic Shock Drug Developers 149
  • Table 24: Common Sepsis Comorbidities Being Targeted by Drug Developers 150
  • Table 25: Biomarkers for Assessment of Immune Status 154
  • Table 26: Key Late-Stage Pipeline Agents for Sepsis and Septic Shock, 2017 173
  • Table 27: Comparison of Therapeutic Classes in Development for Sepsis and Septic Shock, 2016-2026 173
  • Table 28: Product Profile - Selepressin 177
  • Table 29: Reported SAEs of selepressin During Phase II Study 180
  • Table 30: Selepressin SWOT Analysis, 2017 181
  • Table 31: Product Profile - Thrombomodulin (ART-123) 184
  • Table 32: Thrombomodulin Clinical Efficacy Outcomes from RCTs 187
  • Table 33: ART-123 Phase IIb Trial-Important Treatment-Emergent AEs and SAEs Monitored 189
  • Table 34: Thrombomodulin SWOT Analysis, 2017 190
  • Table 35: Product Profile - recAP 192
  • Table 36: Reported Efficacy of Bovine AP in Phase II Studies 193
  • Table 37: recAP SWOT Analysis, 2017 195
  • Table 38: Product Profile - Traumakine 196
  • Table 39: TraumaKine SWOT Analysis, 2017 198
  • Table 40: Product Profile - BMS-936559 200
  • Table 41: Most Frequently Reported AEs and SAEs of BMS-936559* 202
  • Table 42: BMS-936559 SWOT Analysis, 2017 203
  • Table 43: Product Profile - CYT107 205
  • Table 44: Immunological Effects of CYT107 in Cancer and HIV Patients 206
  • Table 45: CYT107 SWOT Analysis, 2017 207
  • Table 46: Product Profile - Cefiderocol 209
  • Table 47: CefiderocolSWOT Analysis, 2017 210
  • Table 48: Product Profile - Toraymyxin 212
  • Table 49: EUPHAS Trial - Toraymyxin Physiological End Points by Treatment Group at Baseline and 72 Hours 214
  • Table 50: EUPHAS Trial - Change in SOFA Scores by Treatment Group After 72 hours 214
  • Table 51: EUPHAS Trial - Event-Free Days and Days Spent in Hospital by Treatment Group 214
  • Table 52: Toraymyxin SWOT Analysis, 2017 217
  • Table 53: Product Profile - CytoSorb 218
  • Table 54: CytoSorb SWOT Analysis, 2017 220
  • Table 55: Innovative Early-Stage Therapies for Sepsis and Septic Shock, 2017 221
  • Table 56: Hospital Indices - ALT-836 225
  • Table 57: Safety Profile - ALT-836 225
  • Table 58: Drugs in Development for Sepsis and Septic Shock, 2017 229
  • Table 59: Clinical Benchmark of Key Sepsis-Specific Treatment Options - Sepsis and Septic Shock 233
  • Table 60: Clinical Benchmark of Key Supportive Care Treatment Options - Sepsis and Septic Shock 234
  • Table 61: Clinical Benchmark of Key Infection Control Treatment Options - Sepsis and Septic Shock 234
  • Table 62: Commercial Benchmark of Key Sepsis-Specific Treatment Options - Sepsis and Septic Shock 236
  • Table 63: Commercial Benchmark of Key Supportive Care Treatment Options - Sepsis and Septic Shock 237
  • Table 64: Commercial Benchmark of Key Infection Control Treatment Options - Sepsis and Septic Shock 238
  • Table 65: Top-Line Sales Forecast ($m) for Sepsis and Septic Shock, 2016-2026 243
  • Table 66: Key Events Impacting Sales for Sepsis and Septic Shock, 2016-2026 247
  • Table 67: Sepsis and Septic Shock Market - Global Drivers and Barriers, 2016?2026 248
  • Table 68: Sales Forecasts ($m) for Sepsis and Septic Shock in the US, 2016-2026 250
  • Table 69: Sales Forecast ($m) for Sepsis and Septic Shock in the 5EU, 2016-2026 254
  • Table 70: Sales Forecasts ($m) for Sepsis and Septic Shock in Japan, 2016-2026 259
  • Table 71: Key Projected Launch Dates for Sepsis and Septic Shock 299
  • Table 72: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 314

List of Figures

  • Figure 1: Global Sales for Sepsis and Septic Shock by Country, 2016 and 2026 12
  • Figure 2: Competitive Assessment of Marketed and Pipeline Agents in Sepsis and Septic Shock, 2016-2026 16
  • Figure 3: Sepsis Definition and Diagnosis Criteria as Outlined in SEPSIS-2 and SEPSIS-3 26
  • Figure 4: Common Causes and Origins of Sepsis 33
  • Figure 5: Common Manifestations of Sepsis 34
  • Figure 6: The Pathogenesis of Sepsis and End-Stage Organ Damage 36
  • Figure 7: Current Understanding of Sepsis and Septic Shock Pathophysiology 40
  • Figure 8: Biomarkers in Bacterial Sepsis Diagnosis 41
  • Figure 9: Potential Target Pathways for Sepsis Treatment 43
  • Figure 10: 7MM, Age-Standardized Diagnosed Incidence of Sepsis (Cases per 100,000 Population), Both Sexes, All Ages, 2016 51
  • Figure 11: 7MM, Age-Standardized Diagnosed Incidence of Septic Shock (Cases per 100,000 Population), Both Sexes, All Ages, 2016 52
  • Figure 12: 7MM, Sources Used and Not Used, Diagnosed Incident Cases of Sepsis 54
  • Figure 13: 7MM, Sources Used and Not Used, Diagnosed Incident Cases of Sepsis/Septic Shock by Causative Agent 55
  • Figure 14: 7MM, Sources Used and Not Used, Organ Dysfunction among Sepsis Cases 56
  • Figure 15: 7MM, Sources Used and Not Used, In-Hospital Mortality Cases of Sepsis 57
  • Figure 16: 7MM, Sources Used and Not Used, Diagnosed Incident Cases of Septic Shock 58
  • Figure 17: 7MM, Sources Used and Not Used, Organ Dysfunction of Septic Shock Cases 59
  • Figure 18: 7MM, Sources Used, In-Hospital Mortality Cases of Septic Shock 60
  • Figure 19: 7MM, Age-Specific Diagnosed Incident Cases of Sepsis, Both Sexes, All Ages, 2016 81
  • Figure 20: 7MM, Sex-Specific Diagnosed Incident Cases of Sepsis, Both Sexes, All Ages, 2016 82
  • Figure 21: 7MM, Diagnosed Incident Cases of Sepsis by Causative Agent, Both Sexes, All Ages, 2016 83
  • Figure 22: 7MM, Organ Dysfunction among Diagnosed Incident Cases of Sepsis, Both Sexes, All Ages, 2016 84
  • Figure 23: 7MM, Age-Specific In-Hospital Mortality Cases of Sepsis, Both Sexes, All Ages, 2016 86
  • Figure 24: 7MM, Age-Specific Diagnosed Incident Cases of Septic Shock, Both Sexes, All Ages, 2016 88
  • Figure 25: 7MM, Sex-Specific Diagnosed Incident Cases of Septic Shock, Both Sexes, All Ages, 2016 89
  • Figure 26: 7MM, Diagnosed Incident Cases of Septic Shock by Causative Agent, Both Sexes, All Ages, 2016 90
  • Figure 27: 7MM, Organ Dysfunction among Diagnosed Incident Cases of Septic Shock, Both Sexes, All Ages, 2016 91
  • Figure 28: 7MM, Age-Specific In-Hospital Mortality Cases of Septic Shock, Both Sexes, All Ages, 2016 93
  • Figure 29: Current Treatment Options for Sepsis and Septic Shock, 2017 98
  • Figure 30: Disease Management Timeline for Sepsis and Septic Shock 101
  • Figure 31: Sepsis and Septic Shock SEPSIS-3 Diagnosis Algorithm 103
  • Figure 32: International Treatment Algorithm Overview for Sepsis, Severe Sepsis, and Septic Shock 104
  • Figure 33: Key Events Shaping Clinical Practice in Sepsis and Septic Shock 108
  • Figure 34: Unmet Need and Opportunity in Sepsis and Septic Shock, 2017 125
  • Figure 35: Current Treatment Options and Associated Biomarkers for Sepsis and Septic Shock, 2017 167
  • Figure 36: Sepsis and Septic Shock - Phase II?III Pipeline, 2017 174
  • Figure 37: Bullseye Diagram of Products in Clinical Development for Sepsis and Septic Shock, 2017 175
  • Figure 38: Competitive Assessment of Marketed and Pipeline Agents for Sepsis-Specific Treatment Options - Sepsis and Septic Shock, 2016-2026 239
  • Figure 39: Competitive Assessment of Marketed and Pipeline Agents for Supportive Care Treatment Options - Sepsis and Septic Shock, 2016-2026 240
  • Figure 40: Competitive Assessment of Marketed and Pipeline Agents for Infection Control Treatment Options - Sepsis and Septic Shock, 2016-2026 241
  • Figure 41: Top-Line Sales for Sepsis and Septic Shock by Country/Region, 2016 and 2026 244
  • Figure 42: Top-Line Sales for Sepsis and Septic Shock by Region, 2016?2026 245
  • Figure 43: Global Sales for Sepsis and Septic Shock by Drug Class, 2016 and 2026 246
  • Figure 44: Sales for Sepsis and Septic Shock by Drug Class in the US, 2016 and 2026 251
  • Figure 45: Sales for Sepsis and Septic Shock by Drug Class in the US, 2016 and 2026 252
  • Figure 46: Sales for Sepsis and Septic Shock by Drug Class in the 5EU, 2016 and 2026 255
  • Figure 47: Sales for Sepsis and Septic Shock by Drug Class in the 5EU, 2016 and 2026 256
  • Figure 48: Global Sales for Sepsis nd Septic Shock by Country in the 5EU, 2016 and 2026 257
  • Figure 49: Global Sales for Sepsis and Septic Shock by Country in the 5EU, 2016?2026 258
  • Figure 50: Sales for Sepsis and Septic Shock by Drug Class in Japan, 2016 and 2026 261
  • Figure 51: Sales for Sepsis and Septic Shock by Drug Class in Japan, 2016 and 2026 262
Back to Top